First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 5, 2006, Pages 595-601

  Ni, Yicheng ^a   Huyghe, Dieter ^b   Verbeke, Kristin ^b   De Witte, Peter A ^b   Nuyts, Johan ^a   Mortelmans, Luc ^a   Chen, Feng ^a   Marchal, Guy ^a   Verbruggen, Alfons M ^b   Bormans, Guy M ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Autoradiography; Hypericin; Necrosis; Radioiodine; SPECT imaging

Indexed keywords

DIAGNOSTIC AGENT; HYPERICIN; IODOHYPERICIN I 123; POLYPHENOL DERIVATIVE; QUINONE DERIVATIVE; TRACER; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; HEART INFARCTION; HISTOCHEMISTRY; HISTOLOGY; HYPERICUM PERFORATUM; IMAGE ANALYSIS; IN VIVO STUDY; ISOTOPE LABELING; LIVER DISEASE; LIVER INFARCTION; MICROSCOPY; NONHUMAN; RABBIT; RADIOACTIVITY; RADIOIODINATION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STAINING; TISSUE NECROSIS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HEART; LIVER; METABOLIC CLEARANCE RATE; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; PERYLENE; PILOT PROJECTS; RABBITS; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 33646396784     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0013-2     Document Type: Article

References (40)

1. Flotats A, Carrió I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging 2003; 30:615-630
2. Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, et al. Sites and mechanisms of localization of technetium-99m phosphorous radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest 1977;60:724-740
3. Khaw BA, Gold HK, Yasuda T, Leinbach RC, Kanke M, Fallon JT, et al. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of cardiac myosin specific antibody. Circulation 1986;74:501-508
4. Khaw BA, Yasuda T, Gold HK, Leinbach RC, Johns JA, Kanke M, et al. Acute myocardial infarction imaging with indium-111 labeled monoclonal antimyosin Fab fragments. J Nucl Med 1987;28:1671-1678
5. Khaw BA, Fallon JT, Beller GA, Haber E. Specificity of localization of myosin-specific antibody fragments in experimental myocardial infarction: histologic, histochemical, autoradiographic and scintigraphic studies. Circulation 1979;60:1527-1531
6. Khaw BA, Scott J, Fallon JT, Cahill SL, Haber E, Homey C. Myocardial injury: quantitation by cell sorting initiated with antimyosin fluorescent spheres. Science 1982;217:1050-1053
7. Khaw BA. The current role of infarct avid imaging. Semin Nucl Med 1999;29:259-270
8. Frist W, Yasuda T, Segall G, Khaw BA, Strauss HW, Gold H, et al. Noninvasive detection of human cardiac transplant rejection with indium-111 anti-myosin (Fab) imaging. Circulation 1987;76:81-85
9. 111In-monoclonal antimyosin antibody studies after the first year of heart transplantation: identification of risk groups for developing rejection during long-term follow-up and clinical implications. Circulation 1990;82:2100-2108
10. Olmos RAV, Carrio I, Hoefnagel CA, Estorch M, Huinink WWT, Lopez-Pousa J, et al. High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction. Nucl Med Commun 2002;23:871-877
11. Dec GW, Palacios IF, Yasuda T, Fallon JT, Khaw BA, Strauss HW, et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990;6:97-104
12. Narula J, Khaw BA, Dec GW, Palacios IF, Southern JF, Fallon JT, et al. Recognition of acute myocarditis masquerading as acute myocardial infarction. N Engl J Med 1992;328:100-104
13. Obrador D, Ballester M, Carrio I, Auge JM, Lopez CM, Bosch I, et al. Active myocardial damage without attending inflammatory response in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1667-1671
14. 111In monoclonal antimyosin antibodies. Circulation 1994;89:2054-2061
15. 99mTc-labeled glucarate. Circulation 1995;95:1577-1584
16. Khaw BA, Nakazama A, O'Donell SM, Pak KY, Narula J. Avidity of technetium-99m glucarate for the necrotic myocardium: in vivo and in vitro assessment. J Nucl Cardiol 1997;4:283-290
17. Nelson J, Schmiedl U, Shanldand E. Metalloporphyrins as tumor-seeking MRI contrast media and as potential selective treatment sensitizers. Invest Radiol 1990;25:S71-S73
18. Ni Y, Marchal G, Yu J, Lukito G, Petre C, Wevers M, et al. Localization of metalloporphyrin induced "specific" enhancement in experimental liver tumors: a comparison between MRI, microangiographic and histologic findings. Acad Radiol 1995;2:687-699
19. Ni Y, Petré C, Miao Y, Yu J, Cresens E, Adriaens P, et al. Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol 1997;32:770-779
20. Maurer J, Strauss A, Ebert W, Bauer H, Felix R. Contrast-enhanced high resolution magnetic resonance imaging of pigmented malignant melanoma using Mn-TPPS4 and Gd-DTPA: experimental results. Melanoma Res 2000;10:40-46
21. Marchal G, Ni Y. Use of porphyrin-complex or expanded porphyrin-complex as an infarction localization diagnosticum. U.S. patent No. 6,013,241. 11 January 2000
22. Marchal G, Ni Y, Herijgers P, Flameng W, Petre C, Bosmans H, et al. Paramagnetic metalloporphyrins: infarct avid contrast agents for diagnosis of acute myocardial infarction by magnetic resonance imaging. Eur Radiol 1996;6:2-8
23. Ni Y, Marchal G, Herijgers P, Flameng W, Petre C, Ebert W, et al. Paramagnetic metalloporphyrins: from enhancers for malignant tumors to markers of myocardial infarcts. Acad Radiol 1996;3:S395-S377
24. Herijgers P, Laycock SK, Ni Y, Marchal G, Bogaert J, Bosmans H, et al. Localization and determination of infarct size by Gd-mesoporphyrin enhanced MRI in dogs. Int J Cardiac Imaging 1997;13:499-507
25. Ni Y, Pislaru C, Bosmans H, Pislaru S, Miao Y, Van de Werf F, et al. Validation of intracoronary delivery of metalloporphyrin as an in vivo "histochemical staining" for myocardial infarction with MR imaging. Acad Radiol 1998;5:S37-41
26. Stillman AE, Wilke N, Jerosch-Herold M. Myocardial viability. Radiol Clin North Am 1999;37:361
27. Pislaru SV, Ni Y, Pislaru C, Bosmans H, Miao Y, Bogaert J, et al. Noninvasive measurements of infarct size after thrombo lysis with a necrosis-avid MRI contrast agent. Circulation 1999;99:690-696
28. Saeed M, Bremerich J, Wendland MF, Wyttenbach R, Weinmann HJ, Higgins CB. Reperfused myocardial infarction as seen with use of necrosis-specific versus standard extracellular MR contrast media in rats. Radiology 1999;213:247-57
29. Lim TH, Choi SI. MRI of myocardial infarction. J Magn Reson Imaging 1999;10:686-693
30. Wendland MF, Saeed M, Lund G, Higgins CB. Contrast-enhanced MRI for quantification of myocardial viability. J Magn Reson Imaging 1999;10:694-702
31. Choi SI, Choi SH, Kim ST, Lim KH, Lim CH, Gong GY, et al. Irreversibly damaged myocardium at MR imaging with a necrotic tissue-specific contrast agent in a cat model. Radiology 2000;215:863-868
32. Lee SS, Goo HW, Park SB, Lim CH, Gong GY, Seo LB, et al. MR imaging of reperfused myocardial infarction: comparison of necrosis-specific and intravascular contrast agents in a cat model. Radiology 2003;226:739-747
33. Ni Y, Miao Y, Bosmans H, Marchal GJ, Semmler W, Baert AL. Evaluation of interventional liver tumor ablation with Gd-mesoporphyrin enhanced magnetic resonance imaging. Radiology 1997;205:P319
34. Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993;85:443-456
35. Chen B, Zupko I, De Witte PA. Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. Int J Oncol 2001;18:737-742
36. 123I]iodohypericin. J Labelled Compd Radiopharm 2001;44:S965-967
37. Ni Y, Adzamli K, Miao Y, Cresens E, Yu J, Periasamy MP, et al. MRI contrast enhancement of necrosis by MP-2269 and Gadophrin-2 in a rat model of liver infarction. Invest Radiol 2001;36:97-103
38. Ni Y, Dymarkowski S, Chen F, Bogaert J, Marchal G. Occlusive myocardial infarction: enhanced or not enhanced with necrosis avid contrast agents at magnetic resonance imaging. Radiology 2002;225:603-605
39. Rude R, Parkey RW, Bonte FJ, Twieg D, Lewis S, Pulido J, et al. Clinical implications of the "doughnut" pattern of uptake in myocardial imaging with technetium-99m stannous pyrophosphate. Circulation 1977;56:146
40. Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of hypericin: a compound with a broad spectrum of biological activities. Med Res Rev 1995;15:111-119